Changes in Roche Board of Directors Montag, 09. Dezember 2013 - 17:45

Changes in Roche Board of Directors

Roche proposes the following Members of the Board of Directors to be re-elected at the AGM, scheduled for 4 March, 2014:

As announced on 16 September, 2013, the Board proposes Christoph Franz to be elected as Chairman of the Board.

William M. Burns (66), Member of the Board of Directors since 2010, has announced that he will not stand for re-election to the Board of Directors.

Roche Chairman Franz B. Humer: “As a long-standing member of the Executive Committee, successful Head of the Pharmaceuticals division and as a board member William M. Burns has made significant contributions to the success of Roche. I want to express my profound gratitude to him for his services.”

About Roche Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012, Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche is the majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

Avec nos salutations distinguées, Bureau des médias pour le groupe

Roche Group Media Relations Grenzacherstrasse 124 4070 Bâle, Suisse

Téléphone : +41 61 688 88 88 Télécopie : +41 61 688 27 75 mailto:roche.mediarelations@roche.com www.roche.com